1. Home
  2. CGEM vs HEPS Comparison

CGEM vs HEPS Comparison

Compare CGEM & HEPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$19.62

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Logo D-Market Electronic Services & Trading

HEPS

D-Market Electronic Services & Trading

N/A

Current Price

$2.86

Market Cap

1.0B

ML Signal

N/A

Company Overview

Basic Information
Metric
CGEM
HEPS
Founded
2016
2000
Country
United States
Turkey
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Catalog/Specialty Distribution
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
CGEM
HEPS
Price
$19.62
$2.86
Analyst Decision
Strong Buy
Hold
Analyst Count
8
1
Target Price
$30.13
$3.07
AVG Volume (30 Days)
524.7K
119.9K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$41.29
Revenue Next Year
$5.20
$27.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.68
$2.15
52 Week High
$19.82
$3.30

Technical Indicators

Market Signals
Indicator
CGEM
HEPS
Relative Strength Index (RSI) 66.45 49.33
Support Level $11.87 $2.74
Resistance Level N/A $2.93
Average True Range (ATR) 0.99 0.11
MACD 0.20 -0.01
Stochastic Oscillator 93.11 44.00

Price Performance

Historical Comparison
CGEM
HEPS

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About HEPS D-Market Electronic Services & Trading

D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. It's portfolio offers its retail customers a wide selection of merchandise including electronics and non-electronics (including books, sports, toys, kids and baby products, cosmetics, furniture, etc). The Group derives revenue from the sales of goods, marketplace revenues and other revenues.

Share on Social Networks: